HRT, Menopause and Longevity: What the Trials Actually Show

The one-sentence version

Menopausal hormone therapy is an effective treatment for menopausal symptoms and bone loss, and after 18 years of follow-up in the Women's Health Initiative it did not change all-cause mortality in either direction¹. It is not a longevity drug. What it is — and this is the part worth getting right — is a symptom and bone treatment whose risk profile depends heavily on when you start it.

Why this field is the cautionary tale

For two decades, observational data suggested hormone therapy protected women's hearts, and it was prescribed accordingly. Then the Women's Health Initiative randomized healthy postmenopausal women to estrogen plus progestin and found the opposite: increased coronary events, stroke and invasive breast cancer. The trial was stopped early².

That reversal is the single best argument in medicine for why mechanism and cohort studies are not enough — and it is directly relevant to everything else this site grades, because most of what is sold as anti-aging rests on exactly the kind of evidence WHI overturned. If you read one thing about why we grade the way we do, read longevity medicine: what's proven versus hyped.

The timing hypothesis, and what tested it

The response to WHI was that its average participant was in her sixties, more than a decade past menopause, with atherosclerosis already established — and that starting therapy near menopause might behave differently. That is the timing hypothesis, and unlike most post-hoc rescues of a failed trial, it was actually tested.

ELITE randomized women by time since menopause and measured the progression of carotid artery thickening. Early-postmenopausal women on estradiol showed slower progression than placebo; late-postmenopausal women showed no such effect³. That is a real, prospectively-designed result supporting the hypothesis — on an imaging surrogate, not on heart attacks.

DOPS, a Danish open-label randomized trial in recently postmenopausal women, reported reduced mortality, heart failure and myocardial infarction after around a decade, without an increase in cancer⁴. It is a genuinely positive cardiovascular result, and it carries real caveats: open-label design and a smaller event count than WHI.

And the long view. Pooled WHI follow-up over 18 years found that hormone therapy was not associated with a difference in all-cause mortality, nor in cardiovascular or cancer mortality¹. Whatever the timing effect does, it does not show up as more years of life.

What it is genuinely good at

None of the above argues against hormone therapy. It argues against buying it for the wrong reason.

• •Vasomotor symptoms — hot flashes and night sweats. This is the core indication and it works.
• •Bone. WHI found reduced fractures on hormone therapy², which is a hard outcome, not a surrogate.
• •Genitourinary symptoms, where local vaginal estrogen carries a different and more favorable risk profile than systemic therapy.

Those are good reasons. "It will extend my life" is not one the evidence supports.

What this means if you are buying it online

Several providers on our board sell women's hormone therapy alongside NAD+, peptides and weight-loss drugs. The questions that decide whether a given offer is a good one are the same ones we grade every row on, and none of them are about the molecule:

• •Is the published price the month-to-month price, or a twelve-month rate with the real figure in an asterisk?
• •Is the clinician review inside that price, or billed separately by a different entity?
• •Are baseline and follow-up labs included, given that dosing is adjusted on them?
• •Is the prescribing clinician named, and is the dispensing pharmacy identified?

The graded answers, per provider, are on our ranking, and the pricing traps that recur across the field are in what longevity care actually costs.

⚠ Compounded "bioidentical" hormone preparations are a distinct product from FDA-approved hormone therapy, and the trials described here tested approved products. A compounded preparation has not been through that evidence base.

The honest summary

Hormone therapy treats symptoms and protects bone. Started near menopause it appears to behave better cardiovascularly than it does started late, with an imaging trial and an open-label trial supporting that and a large randomized trial showing harm when started late. Across eighteen years, it did not change how long women lived.

That is a useful drug and a poor longevity purchase, and the difference is worth the ten minutes it takes to tell them apart — which is the same distinction we draw in TRT and longevity for the other half of the hormone market.